Catalent Pharma Solutions’ Post

The supply chain for cell and gene therapies is complex and requires next-level precision and oversight. Learn more about what you can do to bridge the gap between manufacturing and delivery of the finished therapy to the patient. https://ow.ly/F8Ki50S90rl

The supply chain for cell and gene therapies is complex and requires next-level precision and oversight. Learn more about what you can do to bridge the gap between manufacturing and delivery of the finished therapy to the patient. https://ow.ly/F8Ki50S90rl

The supply chain for cell and gene therapies is complex and requires next-level precision and oversight. Learn more about what you can do to bridge the gap between manufacturing and delivery of the finished therapy to the patient. https://ow.ly/F8Ki50S90rl

The supply chain for cell and gene therapies is complex and requires next-level precision and oversight. Learn more about what you can do to bridge the gap between manufacturing and delivery of the finished therapy to the patient. https://ow.ly/F8Ki50S90rl

The supply chain for cell and gene therapies is complex and requires next-level precision and oversight. Learn more about how to bridge the gap between manufacturing and delivering the finished therapy to the patient. https://ow.ly/j9qA50SOaTx

The supply chain for cell and gene therapies is complex and requires next-level precision and oversight. Learn more about what you can do to bridge the gap between manufacturing and delivery of the finished therapy to the patient. https://ow.ly/kc4G50Qznic

Hear from Tom Smith today, at 11.30am (EST) at the Cell and Gene Therapy Pricing and Reimbursement Summit. Tom will be discussing how Uniphar are accelerating global patient access to cell and gene therapies. #CellandGeneTherapy #PricingReimbursement #MarketAccess #ExpandedAccess

The supply chain for cell and gene therapies is complex and requires next-level precision and oversight. Learn more about what you can do to bridge the gap between manufacturing and delivery of the finished therapy to the patient. https://ow.ly/kc4G50Qznic

Explore key manufacturing challenges faced in autologous commercial cell and gene therapies in this cross-sector collaborative article written by my colleagues at PA Consulting. Dr. Paolo Siciliano, Martin Sowden, Shanton Wilcox, and Harry Ustik came together to publish this article in SupplyChainBrain. #ManufacturingChallenges #GeneTherapy

Learn about the intricacies of manufacturing in the cell and gene therapy space in this article in SupplyChainBrain written by my colleagues Dr Paolo Siciliano, Martin Sowden, Shanton Wilcox, and Harry Ustik. They break it down into 5 key areas of opportunity for manufacturers in this space. #AutologousCommercialCellTherapy #GeneTherapy #MedicalManufacturingChallenges